IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(30 sites)

United States

St. Anthony's Hospital - BayCare Health System, St. Petersburg, Florida

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

University of Chicago Medical Center, Chicago, Illinois

Northwell Health Cancer Institute / Center for Novel Cancer Therapeutics, Lake Success, New York

Millennium Research & Clinical Development, Houston, Texas

UW Carbone Cancer Center - Cancer Connect, Madison, Wisconsin

France

Angers University Hospital Center, Angers

University Hospital Center Caen, Caen

Hospital Calmette, Lille

CHU de Limoges, Limoges

Leon Berard Center, Lyon

Marseille University Hospital Center - North Hospital, Marseille

Rennes University Hospital Center - Hospital Pontchaillou, Rennes

Charles Nicolle Hospital, Rouen

Gustave Roussy, Villejuif

Greece

Henry Dunant Hospital Center, Athens

University General Hospital "Attikon", Athens

University General Hospital of Ioannina, Ioannina

University General Hospital of Patras, Pátrai

Hungary

Koranyi National Institute of Pulmonology, 14th Department of Pulmonology, Budapest

Veszprem County Pulmonology Institute, Farkasgyepű

Petz Aladar University Teaching Hospital, Department of Pulmonology, Győr

Jasz-Nagykun-Szolnok County Hetenyi Geza Hospital-Clinic, Department of Oncology, Szolnok

Pulmonology Institute Torokbalint, Törökbálint

Poland

University Teaching Hospital in Bialystok, 2nd Department of Lung Diseases and Tuberculosis, Bialystok

John Paul II Specialist Hospital in Krakow, Krąków

Mandziuk Slawomir - Specialist Medical Practice, Lublin

Eugenia and Janusz Zeyland Wielkopolskie Centre of Pulmonology and Thoracic Surgery, Poznan

Specialist Hospital in Prabuty Sp. z o.o. (LLC), Prabuty

Military Institute of Medicine - National Research Institute, Warsaw